Bioventus (NASDAQ:BVS) executives outlined the company’s portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering U.S. medtech and healthcare IT.
Mark Singleton, Bioventus’ senior vice president and chief financial officer, described the company as a $568 million revenue business as of 2025, with 2026 guidance of $605 million. He said Bioventus participates in markets totaling more than $6 billion and has improved its financial profile over the past several years.
